Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer
Conditions: Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Recurrent Bladder Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage III Bladder Urothelial Carcinoma; Stage III Urethral Cancer; Stage IV Bladder Urothelial Carcinoma; Stage IV Urethral Cancer; Urethral Urothelial CarcinomaInterventions: Drug: Pembrolizumab; Drug: Docetaxel; Drug: Gemcitabine HydrochlorideSponsors: University of California, Davis; National Cancer Institute (NCI); Merck Sharp & Dohme Corp.Not yet recruiting - verified May 2015
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Docetaxel | Research | Taxotere | Ureter and Renal Pelvis Cancer | Urethral Cancer